Search Results
Jul 13, 2026, 04:53 ET Boostimmune Secures Japanese Patent for Sequence-Independent TCTP Antibody Technology Targeting MDSC Accumulation
limited to specific antibody CDRs or amino acid sequences, but are defined by function and therapeutic usePatent claims cover inhibition of PMN-MDSC accumulation as well as cancer therapeutics and therapeutic compositions containing the inhibitorStrengthens the core intellectual property
More news about: Boostimmune
Apr 20, 2026, 07:30 ET TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
nephropathy (PMN) with planned expansions into other indications.The agreement builds on the productive collaboration between the two companies. In April 2025, TJ Bio joined two Biogen-sponsored Phase 3 International Multi-Center Trials (IMCT) evaluating felzartamab in IgAN and PMN in China. IgAN
More news about: TJ Biopharma
Mar 23, 2026, 08:30 ET The Glomerular Revolution: Understanding the New Wave of Breakthroughs in Rare Kidney Diseases, Upcoming Webinar Hosted by Xtalks
improve decision-making in rare kidney disease. The featured speakers will provide an overview of rare renal diseases, including IgAN, C3G, FSGS and PMN, and discuss how newer treatments are changing care. Attendees will gain insight into the molecular pathways that drive glomerular damage and their implications
More news about: Xtalks
Dec 02, 2025, 03:00 ET Power Metallic Intercepts 4.40 Meters of 12.18% Cu (14.34% CuEqRec) included within 20.40 Meters of 2.91% Cu (3.58% CuEqRec) in Hole 25-029b at Lion, and Completes the Extension of PN-24-064 to define large off-hole BHEM anomaly
1)Drilling at the Nisk East target includes holes PMN-25-005 thru PMN-25-011. Modest intersections of Ni-Cu-Pd mineralization was intersected in holes PMN-25-005, 008 and 011, including 4.00m of 2.34% CuEqRec1 in hole PMN-25-005. The Nisk East area is now being re-assessed with the recent
More news about: Power Metallic Mines Inc.
Nov 21, 2025, 06:29 ET PTS Announces Official Launch of PMN on Republic -- Japan's First Compliant STO Offered in the United States
product, PMN (Pivotal Mining Note), on Republic, marking a significant milestone for the global digital securities industry. PMN becomes the first Japan-originated Security Token Offering (STO) to be compliantly
More news about: Pivotal Trend Service Co., Ltd.
Nov 21, 2025, 06:20 ET PTS Announces Official Launch of PMN on Republic -- Japan's First Compliant STO Offered in the United States
product, PMN (Pivotal Mining Note), on Republic, marking a significant milestone for the global digital securities industry. PMN becomes the first Japan-originated Security Token Offering (STO) to
More news about: Pivotal Trend Service Co., Ltd.
Nov 06, 2025, 11:05 ET 再鼎醫藥公布 2025年第三季度財務業績和近期公司進展
(APRIL/BAFF) 原發性膜性腎病（ pMN ）：再鼎醫藥將於2025年第四季度在大中華區加入povetacicept用於pMN的全球關鍵性2/3期OLYMPUS研究。 IgA
More news about: 再鼎醫藥
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
Pivotal Mining Note (PMN), will be offered under Regulation D Rule 506(c) and Regulation S, targeting U.S. accredited and eligible international investors. Issued by Japan-based PTS and offered via Republic's platform. PMN provides structured, long-term exposure to Bitcoin
More news about: Pivotal Trend Service Co., Ltd.
Oct 28, 2025, 19:00 ET PTS to Launch Japan-Origin Bitcoin Mining Investment Product via Republic Platform Under U.S. Regulation
Pivotal Mining Note (PMN), will be offered under Regulation D Rule 506(c) and Regulation S, targeting U.S. accredited and eligible international investors. Issued by Japan-based PTS and offered via Republic's platform. PMN provides structured, long-term exposure to Bitcoin
More news about: Pivotal Trend Service Co., Ltd.
Oct 22, 2025, 17:31 ET Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
initiated dosing in the global Phase III PROMINENT trial evaluating felzartamab, an anti-CD38 antibody, versus tacrolimus in adults with PMN. With no approved therapies for PMN, this 180-patient trial aims to deliver results by 2029, highlighting felzartamab's differentiated potential.
More news about: DelveInsight Business Research, LLP
Sep 18, 2025, 09:10 ET Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
(OTCQB: AVAI), HCW Biologics Inc. (NASDAQ: HCWB), Solid Biosciences Inc. (NASDAQ: SLDB), ProMIS Neuorsciences, Inc. (NASDAQ: PMN), and uniQure N.V. (NASDAQ: QURE).
More news about: USA News Group